Biopharmaceutical News and Research

RSS

Sartorius launches new ambr 250 modular bioreactor vessel for cell and gene therapy applications

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, today launched a new vessel for its ambr 250 modular benchtop automated mini bioreactor system.

From Sartorius 28 Jun 2019

Quanterix announces agreement to acquire UmanDiagnostics, world’s leading neurofilament light (Nf-l) antibody supplier

Quanterix announce agreement to acquire privately held UmanDiagnostics AB for $22.5 million.

From Quanterix 26 Jun 2019

PhoreMost and C4XD sign neurodegeneration drug discovery collaboration agreement

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and C4X Discovery Holdings plc, a pioneering drug discovery company, today announced they have signed a neurodegeneration drug discovery collaboration agreement.

From PhoreMost 25 Jun 2019

Investigational drug for treatment of sickle cell disease shows early promise in clinical trials

An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers at the European Hematology Association Congress in Amsterdam this week.

20 Jun 2019

Researchers identify new clues on tissue damage in rheumatoid arthritis and lupus

Research supported by the Accelerating Medicines Partnership on Rheumatoid Arthritis and Systemic Lupus Erythematosus provides new insights into tissue damage for these autoimmune conditions.

19 Jun 2019

Topical cream found to be effective in reversing the effects of vitiligo

A nationwide phase II clinical trial, coordinated out of Tufts Medical Center in Boston, has found that a topical cream was extremely effective in reversing the effects of vitiligo, a relatively common autoimmune disease that causes loss of skin pigmentation.

17 Jun 2019

NCCN and AstraZeneca collaborate to improve care processes for lung cancer patients

The National Comprehensive Cancer Network Oncology Research Program and AstraZeneca, a global, science-led biopharmaceutical company, are collaborating to seek proposals for improving care processes for patients with unresectable stage III and stage IV non-small cell lung cancer.

31 May 2019

Research provides new options for treatment of multi-drug resistant infections

A new study, published in 'Antimicrobial Agents and Chemotherapy' conducted by a University of Liverpool led research consortium, has helped develop a new treatment option for some multi-drug resistant infections.

30 May 2019

Study discovers origin of neurofibromas that develop throughout the skin of NF1 patients

A study published today in PLOS ONE discovered the origin of severely disfiguring masses of cells, called neurofibromas, that gradually develop throughout the skin of patients afflicted with Neurofibromatosis 1.

22 May 2019

Electron microscopy project could revolutionize the search for new drugs

The search for new drugs to combat diseases more effectively could be revolutionized through a new £30 million electron microscopy project.

17 May 2019

Sartorius Stedim Biotech launches new SIMCA 16 software for multivariate data analytics

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry today announced the new SIMCA® 16 software for multivariate data analytics is available from its subsidiary Sartorius Stedim Data Analytics.

From Sartorius 9 May 2019

Sartorius Stedim Biotech introduces new ambr 15 cell culture microbioreactor system

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, is introducing its new generation of ambr 15 cell culture automated microbioreactor system.

From Sartorius 3 May 2019

Mulvaney: Trump brought down drug prices for the first time in 50 years

President Donald Trump announced last month that the GOP will become “the party of health care,” and news reports suggest he intends to make it a top issue in his reelection campaign.

15 Apr 2019

Bruker highlights innovative NMR capabilities and products at ENC 2019

At ENC 2019, Bruker highlights innovative NMR capabilities and products for biomolecular, materials research and pharmaceutical applications, as well as new scientific software solutions.

From Bruker BioSpin Group 10 Apr 2019

UTMB receives grant to combat highly-lethal hemorrhagic fever viruses

The University of Texas Medical Branch at Galveston, Profectus Biosciences, Vanderbilt University Medical Center, Mapp Biopharmaceutical and Genevant Sciences Corp. have been awarded up to $35 million to advance the development of rapid-acting vaccines and broad-spectrum treatments of the highly-lethal hemorrhagic fever viruses Ebola and Marburg.

9 Apr 2019

New clinical trials to investigate combination immunotherapy for treating advanced cancers

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly-impossible-to-treat cancer into a disease that can be corralled into remission.

8 Apr 2019

Celltrion and iProgen Biotech announce partnership for development of novel ADCs

On April 8, Celltrion and the Canada-based iProgen Biotech Inc. announced to agree to partner for the development of novel ADCs against validated antibody targets, including HER2 and CD20.

8 Apr 2019

NIAID awards $22 million grant to develop antibody-based therapies against lethal viruses

The National Institute of Allergy and Infectious Diseases has awarded an international consortium led by Albert Einstein College of Medicine, part of Montefiore, a five-year, $22 million grant to develop antibody-based therapies against four highly lethal viruses for which there are no approved vaccines or treatments.

4 Apr 2019

Study provides framework for developing Ebola virus therapeutic under FDA Animal Rule

The U.S. Army Medical Research Institute of Infectious Diseases today announced that, for the first time, the U.S. Food and Drug Administration has provided formal regulatory agreement for use of an animal model to support development of a drug candidate, remdesivir, for treating deadly Ebola virus infections.

29 Mar 2019

Sartorius wins double award at Fisher Scientific European Sales Conference for the second time

Sartorius was once again a double award winner at the Fisher Scientific European Sales Conference in Karpacz, Poland.

From Sartorius 25 Mar 2019